Browse Category

Press Releases - Page 4

Welcome to the "Press Releases" category on NowadAIs, your premier source for the latest updates in the world of artificial intelligence. Our carefully curated Press Releases provide a comprehensive overview of the most recent breakthroughs, partnerships, and product launches in the AI industry. Whether you're a tech enthusiast, an industry professional, or someone curious about the evolving landscape of artificial intelligence, our Press Release section ensures you stay informed about the pivotal developments shaping the future. Explore in-depth analyses, official statements, and key insights from industry leaders, all in one place, to keep your finger on the pulse of AI innovation
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

August 11, 2026
Ascletis Pharma Inc. has initiated two Phase I studies in the U.S. for obesity treatment: ASC36, a once-monthly to once-quarterly amylin receptor peptide agonist, and ASC36_35FDC, a once-monthly fixed dose combination of
1 2 3 4 5 6 23

Categories

Follow us on Facebook!

Go toTop